NASDAQ:ANIX

Anixa Biosciences Q4 2024 Earnings Results & Report

Anixa Biosciences logo
$2.44 -0.16 (-6.15%)
As of 04:00 PM Eastern

Anixa Biosciences beat analyst earnings expectations in its Q4 2024 results, released January 10, 2025. The company reported EPS of -$0.09 versus the -$0.11 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Anixa Biosciences EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Anixa Biosciences' Q4 2026 earnings is estimated for Monday, January 11, 2027, based on past reporting schedules, with a conference call scheduled on Tuesday, January 12, 2027 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Anixa Biosciences Q4 2024 Earnings FAQ

Anixa Biosciences (NASDAQ:ANIX) reported earnings of -$0.09 per share for Q4 2024, beating the consensus estimate of -$0.11. The report was announced on Friday, January 10, 2025.

Anixa Biosciences' next earnings date is estimated for Monday, January 11, 2027. MarketBeat tracks confirmed and estimated earnings dates for Anixa Biosciences on the company's earnings history page.

Anixa Biosciences Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners.

The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.

Anixa has also pursued cancer-detection technologies through its Cchek platform. The company is led by Amit Kumar, who serves as chairman and chief executive officer.

View Anixa Biosciences Profile